Cargando…
The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma
Dedifferentiated liposarcomas (DDLPS) are highly resistant to conventional chemo- and radiotherapies, with surgical resection remaining the classic treatment strategy; therefore there is a pressing need for novel anti-DDLPS targeted chemotherapeutics. Hepatocyte growth factor receptor (Met) expressi...
Autores principales: | Bill, Kate Lynn J., Garnett, Jeannine, Ma, Xiaoyan, May, Caitlin, Bolshakov, Svetlana, Lazar, Alexander J., Lev, Dina, Pollock, Raphael E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520775/ https://www.ncbi.nlm.nih.gov/pubmed/26006023 http://dx.doi.org/10.1038/labinvest.2015.62 |
Ejemplares similares
-
AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas
por: May, Caitlin D., et al.
Publicado: (2015) -
miR-133a function in the pathogenesis of dedifferentiated liposarcoma
por: Yu, Peter Y., et al.
Publicado: (2018) -
Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma
por: Hwang, Ju-Ae, et al.
Publicado: (2014) -
An experimental model for the study of well differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors
por: Peng, Tingsheng, et al.
Publicado: (2010) -
Cracking the riddle of dedifferentiated liposarcoma: is EV-MDM2 a key?
por: Casadei, Lucia, et al.
Publicado: (2020)